The present application provides an IRM compound 4-amino-±,±-dimethyl-2-ethoxymethyl-1H-imidazo[4,5-c]quinolin-1-ethanol for use in treating cutaneous metastases, wherein the IRM compound is administered topically and the cutaneous metastasis is derived from a solid breast cancer tumor.